Speculation regarding a potential takeover of French biotech Abivax by Eli Lilly intensified on December 22, 2025.
Fresh reports allege that Eli Lilly representatives met with France’s Treasury department in early December. The purpose of the meeting was to discuss the regulatory framework for a possible acquisition.
The revived takeover talk triggered a significant market reaction for Abivax. Its stock climbed 9% in Paris trading, and U.S. shares jumped 10% in premarket activity.
Eli Lilly has not commented on what it termed "business development activity." Abivax stated it does not comment on market rumors.